Vaccines and Global Health: The Week in Review
21 October 2023 :: Issue 723
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 27,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Milestones, Perspectives
:: WHO
:: Organization Announcements
:: Journal Watch
:: Pre-Print Servers
:: Think Tanks
**Joint Statement on Action plan to drive equitable expansion of immunisation in Africa**

Geneva, 16 October 2023

The African Union Commission (AUC), Africa Centres for Disease Control and Prevention (Africa CDC) and Gavi, the Vaccine Alliance last week concluded a three-day forum to outline a pathway towards extensive collaboration in alignment of the tripartite Memorandum of Understanding signed between the organizations in May 2023.

Through the MoU, the three organizations commit to increase access and accelerate the uptake of life-saving vaccines across African Union member states, by leveraging their collective resources, expertise and expansive networks to collaboratively address a broad range of health issues.

Senior leadership from all three organisations as well as technical experts, contributed to the action-oriented sessions, which were aligned across the following cross-cutting issues:

- **Fostering sustainable and equitable systems for immunisation**, including reaching zero dose children, overcome barriers, and building a resilient health workforce
- **Building public trust and confidence in immunization**, including demand generation and social behavioral change, and aligning immunization-related communications and advocacy
- Realizing the continental vision to **expand vaccine manufacturing in Africa**, including the facilitation of efficient regulatory pathways and timely authorisations of vaccines and efficient, effective pharmacovigilance
- **Strengthening diagnostic and disease surveillance capacity** for epidemic prone vaccine-preventable diseases

In addition to these discussions, the delegations also engaged in preliminary discussions on the design of Gavi’s next five-year strategic period, “Gavi 6.0”, which will run from 2026-2030, as well as ways to align on pandemic prevention, preparedness and response activities.

The AUC and Africa CDC delegation was led by Dr Ahmed Ogwell Ouma, Ag. Deputy Director General, Africa CDC. Gavi’s delegation was led by Pascal Barollier, Chief Engagement Officer and Thabani Maphosa, Managing Director, Country Programmes Delivery.

“We have come together to give life to the tripartite MoU and secure the health of the continent of Africa. We have committed to work in synergy and give Africa tangible results for immunisation in the shortest time,” said Dr Ahmed Ogwell Ouma, Deputy Director General of the Africa CDC.

“The work our organizations undertake is intrinsically linked, and it is critical that we have come together in service of the AUC’s continental vision for public health, the New Public Health Order,” said Thabani Maphosa, Managing Director of Country Programmes Delivery at Gavi. “This week’s workshop was the time to turn our deep commitment to collaboration into a tangible plan of action. Gavi is proud to be a partner to the African Union Commission and Africa CDC, and we are excited to be expanding this partnership into so many aspects of our work.”
Global regulatory reforms to promote equitable vaccine access in the next pandemic

Richard Mahoney, Peter J. Hotez, Maria Elena Bottazzi

PLoS Global Public Health | published 18 Oct 2023
https://doi.org/10.1371/journal.pgph.0002482

Abstract
There is broad consensus that the global response to the Covid-19 pandemic was inadequate, leading to unacceptable levels of avoidable morbidity and mortality. Three strategic missteps led to the lack of equitable vaccine access: The heavy reliance on commercial vaccine manufacturers in high-income countries (HICs) versus low- and middle-income countries (LMICs); the emergence of vaccine nationalism restricting and delaying the supply of vaccines to LMICs; and an inadequate support or recognition for LMIC national regulatory authorities. To avoid these inequities in a future pandemic, we focus on three successful vaccine development and technology transfer case studies—the Hepatitis B vaccine produced in South Korea in the 1980s; the Meningitis A vaccine for Africa led by Program for Appropriate Technologies in Health (PATH) and the World Health Organization (WHO) in the 2000s; and a recombinant SARS CoV-2 protein-based vaccine technology from the Texas Children's Hospital transferred to India and to Indonesia. In addition to expanding support for academic or non-profit product development partnerships, our analysis finds that an essential step is the strengthening of selected LMIC regulatory systems to become Stringent Regulatory Authorities (SRAs), together with a re-prioritization of the WHO Prequalification (PQ) system to ensure early vaccine availability in LMICs especially during pandemics. Advancing LMIC National Regulatory Authorities (NRAs) to Stringent Regulatory Authorities (SRAs) status will require substantial resources, but the benefits for future pandemic control and for health in LMIC would be immense. We call on the WHO, United Nation (UN) agencies and SRAs, to collaborate and implement a comprehensive roadmap to support LMIC regulators to achieve stringent status by 2030.

Conclusions
The vaccine development strategy of the COVID-19 pandemic in which vast resources were allocated mostly to HIC producers to take over and finalize the development of vaccines that had initially been developed largely in academia and government was a failure in terms of meeting the needs of people in LMICs. Vaccine nationalism and the inertia of the global health enterprise greatly impeded LMIC access to needed vaccines. Therefore, a major overhaul of the global pandemic response ecosystem such as proposed by Torreele [10] will be necessary.

Ensuring that people in LMICs can receive vaccines rapidly after the outbreak of a pandemic will depend in large part on the availability of vaccine producers in LMICs. The greatest barrier to LMIC producers being able to supply other LMICs is the necessity to meet regulatory requirements and, especially, to obtain WHO PQ. The highest priority should be capacity building and strengthening support to selected LMIC NRAs to help them become SRAs. In the meantime, additional assistance should be provided to LMIC manufacturers so they can expeditiously obtain PQ. WHO has recognized this need and is prepared to provide technical assistance to LMIC manufacturers [48]. However, this program has limited funding.

A second barrier is the lack of recognition for academic-based and non-profit product development partnerships as innovators that can work hand-in-glove with LMIC vaccine producers. The three examples here provide essential case studies.

Pandemic vaccine development considerations could be seen as the justification for a broad program to enhance LMIC NRAs to SRAs [49]. Implementing such a program would be a necessary step for
LMICs to achieve greater self-sufficiency in developing, approving, supplying and monitoring needed vaccines, drugs and devices for their populations and especially for the diseases that are important in their countries. In turn, to maintain SRA status within an LMIC, would require considerable resources and time and should be seen as necessary for improving health in LMICs in addition to ensuring a more effective response to future pandemics [50].

Furthermore, the existence of SRAs in vaccine producing LMICs and, in the meantime, of a robust rapidly acting WHO PQ system that gives priority to LMIC producers will facilitate and encourage vaccine developers, especially those in academia or the non-profit world, to prioritize the transfer of their vaccine to LMIC producers.

Our recommendations address one of the major issues that impeded an effective response to the COVID-19 pandemic, the urgency to strengthen regulatory systems in LMICs to become SRAs, together with a re-prioritization of the WHO Prequalification (PQ) system to ensure rapid actions for LMICs especially during pandemics. To address these hurdles, we call on the WHO, UN agencies and SRAs, to collaborate and implement a comprehensive roadmap to support LMIC regulators, including the AMA, to achieve stringent status by 2030. The designation of LMIC-based SRAs will empower local vaccine innovations and facilitate vaccine development with regionally appropriate frameworks leading to accessible vaccines.

Regulatory considerations on artificial intelligence for health

WHO 2023 :: 61 pages
ISBN: 9789240078871 (electronic version) 9789240078888 (print version)
PDF: 9789240078871-eng.pdf (753.8Kb)

...This publication, which is based on the work of the WG-RC, aims to deliver an overview of regulatory considerations on AI for health that covers the following six general topic areas: documentation and transparency, the total product lifecycle approach and risk management, intended use and analytical and clinical validation, data quality, privacy and data protection, and engagement and collaboration. This overview is not intended as guidance or as a regulatory framework or policy. Rather, it is a discussion of key regulatory considerations and a resource that can be considered by all relevant stakeholders – including developers who are exploring and developing AI systems, regulators and policy-makers who in the process of identifying approaches to manage and facilitate AI systems, manufacturers who design and develop AI-enabled medical devices, and health practitioners who deploy and use such medical devices and AI systems.

Consequently, the WG-RC recommends that stakeholders take into account the following considerations as they continue to develop frameworks and best practices for the use of AI in health care and therapeutic development:

1. **Documentation and transparency:** Pre-specifying and documenting the intended medical purpose and development process – such as the selection and use of datasets, reference standards, parameters, metrics, deviations from original plans and updates during the phases of development – should be considered in a manner that allows for the tracing of the development steps as appropriate. A risk-based approach should be considered also for the level of documentation and record-keeping utilized for the development and validation of AI systems.

2. **Risk management and AI systems development lifecycle approaches:** A total product lifecycle approach should be considered throughout all phases in the life of an AI system, namely: pre-market development management, post-market surveillance and change management. In
addition, it is essential to consider a risk management approach that addresses risks associated with AI systems, such as cybersecurity threats and vulnerabilities, underfitting, algorithmic bias etc.

3. Intended use, and analytical and clinical validation: Initially, providing transparent documentation of the intended use of the AI system should be considered. Details of the training dataset composition underpinning an AI system – including size, setting and population, input and output data and demographic composition – should be transparently documented and provided to users. In addition, it is key to consider demonstrating performance beyond the training and testing data through external analytical validation in an independent dataset. This external validation dataset should be representative of the population and setting in which it is intended to deploy the AI system and should be independent of the dataset used for developing the AI model during training and testing. Transparent documentation of the external dataset and performance metrics should be provided. Furthermore, it is important to consider a graded set of requirements for clinical validation based on risk. Randomized clinical trials are the gold standard for evaluation of comparative clinical performance and could be appropriate for the highest-risk tools or where the highest standard of evidence is required. In other situations, prospective validation can be considered in a real-world deployment and implementation trial which includes a relevant comparator that uses accepted groups. Finally, a period of more intense post-deployment monitoring should be considered through post-market surveillance and market surveillance for AI systems.

4. Data quality: Developers should consider whether available data are of sufficient quality to support the development of the AI system to achieve the intended purpose. Furthermore, developers should consider deploying rigorous pre-release evaluations for AI systems to ensure that they will not amplify any of the issues discussed in Section 5.4 of this document, such as biases and errors. Careful design or prompt troubleshooting can help identify data quality issues early and can prevent or mitigate possible resulting harm. Stakeholders should also consider mitigating data quality issues and the associated risks that arise in health-care data, as well as continue to work to create data ecosystems to facilitate the sharing of good-quality data sources.

5. Privacy and data protection: Privacy and data protection should be considered during the design and deployment of AI systems. Early in the development process, developers should consider gaining a good understanding of applicable data protection regulations and privacy laws and should ensure that the development process meets or exceeds such legal requirements. It is also important to consider implementing a compliance programme that addresses risks and ensures that the privacy and cybersecurity practices take into account potential harm as well as the enforcement environment.

6. Engagement and collaboration: During development of the AI innovation and deployment roadmap it is important to consider the development of accessible and informative platforms that facilitate engagement and collaboration among key stakeholders, where applicable and appropriate. It is fundamental to consider streamlining the oversight process for AI regulation through such engagement and collaboration in order to accelerate practice-changing advances in AI...

Polio – PHEIC

Polio this week as of 18 Oct 2023 - GPEI
Headlines [Selected]
:: Tuesday, 24 October is World Polio Day, a chance to raise awareness and resources to help deliver a polio-free world in the very near term. To mark the day, partners and stakeholders around the world are organizing events, bringing together public and civil society in a common goal. For all individual eradicators and stakeholders: thank you for everything you do to make the dream of a polio-free world a reality. If you would like to make a personal, voluntary donation towards the effort, we would invite you to contribute via Rotary International’s End Polio Now campaign, a key partner alongside WHO and others in the Global Polio Eradication Initiative. Each donation made to Rotary’s End Polio Now effort is matched 2:1 by the Bill & Melinda Gates Foundation to maximise its effect. As such, if you give US$10 to the effort, as an example, the amount becomes US$30, and with that, 60 children will be vaccinated in the remaining affected countries. Thank you for everything that you do! We wish you a very successful World Polio Day!
:: The Global Polio Eradication Initiative would like to offer our heartfelt congratulations to Professor Rose Leke for receiving the 2023 Virchow Prize for Global Health, for her outstanding contributions to advancing global health, including polio eradication. Professor Leke is the Chair of the Africa Regional Certification Commission and member of the Global Commission for Certification of Poliomyelitis Eradication (GCC).

Summary of new polioviruses this week, cases and positive environmental isolates:
- Cameroon: two cVDPV2 positive environmental samples
- Central African Republic: one cVDPV2 case
- Côte d’Ivoire: two cVDPV2 cases and four positive environmental samples
- DR Congo: three cVDPV1 and three cVDPV2 cases, two cVDPV2 positive environmental samples
- Madagascar: three cVDPV1 positive environmental samples
- Mali: one cVDPV2 case
- Yemen: one cVDPV2 case

::: Coronavirus [COVID-19]
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Numbers at a glance
Last update: 18 Oct 2023
Confirmed cases :: 771 407 825
Confirmed deaths :: 6 972 152
Vaccine doses administered: 13 516 282 548

::: Our World in Data
:: 70.5% of the world population has received at least one dose of a COVID-19 vaccine.
:: 13.52 billion doses have been administered globally, and 37,306 are now administered each day.
:: 32.6% of people in low-income countries have received at least one dose.
WHO & Regional Offices [to 21 Oct 2023]
https://www.who.int/news
Selected News/Announcements/Statements
21 October 2023 Statement
Joint statement by UNDP, UNFPA, UNICEF, WFP and WHO on humanitarian supplies crossing into Gaza

20 October 2023 Departmental news
WHO and ECHO discuss the way forward in strengthening their partnership and innovative ways of cooperation

20 October 2023 Departmental news
Türkiye regulatory system becomes fourteenth country to reach WHO Maturity Level 3

19 October 2023 News release
WHO releases new list of essential diagnostics; new recommendations for hepatitis E virus tests, personal use glucose meters

19 October 2023  Departmental news
13 critical interventions that support countries to address antimicrobial resistance in human health

19 October 2023  News release
WHO outlines considerations for regulation of artificial intelligence for health

17 October 2023  Statement
WHO statement on attack on Al Ahli Arab Hospital and reported large-scale casualties

17 October 2023  Departmental news
First meeting of the Technical Advisory Group on Genomics

17 October 2023  Departmental news
United Nations partners call for investments in self-care interventions to improve sexual and reproductive health

17 October 2023  Statement
Health leaders at the WHS support WHO commitment to build climate resilient, low carbon sustainable health systems (ATACH)

16 October 2023  Departmental news
WHO announces the elimination of lymphatic filariasis as a public health problem in the Lao People’s Democratic Republic

16 October 2023  Departmental news
WHO announces the release of ScreenTB - a web-based tool to help countries prioritize action for TB screening and prevention

:::::

WHO Regional Offices
Selected Press Releases, Announcements
WHO African Region
No new digest content identified.

WHO Region of the Americas  PAHO
:: 18 Oct 2023
PAHO joins forces with Canada to reverse declining immunization against vaccine-preventable diseases in Haiti

Washington, D.C., 18 October 2023 (PAHO) – The Pan American Health Organization (PAHO) and the Government of Canada announced today the launch of a joint initiative to support Haiti to expand vaccination against potentially lethal vaccine-preventable diseases, including polio, measles, diphtheria and tetanus The partnership, which is part of...

:: 17 Oct 2023
IARC and PAHO launch the 1st edition of the Latin America and the Caribbean Code Against Cancer

Lyon, France / Washington DC, 17 October 2023 – The Pan American Health Organization (PAHO) and the International Agency for Research on Cancer (IARC) today launched the first edition of the
Latin America and the Caribbean Code Against Cancer. The new Code, which forms part of the World Code Against Cancer, aims to help reduce the burden of cancer...

:: 17 Oct 2023

PAHO Director underscores transatlantic partnerships to address present and future health challenges

Berlin, Germany, 17 October 2023 (PAHO) - At the 2023 World Health Summit in Berlin, the Pan American Health Organization (PAHO) Director, Jarbas Barbosa, highlighted the need for strong partnerships across regions to increase health access and equity, especially as countries work to increase preparedness and response to future health threats. “...

WHO South-East Asia Region SEARO
No new digest content identified.

WHO European Region EURO
:: 21 October 2023 News release
Unlocking the future of healthy ageing: The Lisbon Outcome Statement
:: 20 October 2023 News release
Addressing the growing needs of Kazakhstan’s digital health workforce
:: 18 October 2023 News release
Despite progress, challenges persist in advancing sexual and reproductive health and rights in the WHO European Region

WHO Western Pacific Region
:: 20 October 2023 Media release
Region’s health leaders agree on actions to enhance communication for health, strengthen a...
:: 19 October 2023 Media release
Health leaders take steps to strengthen health security in Asia-Pacific
:: 17 October 2023 News release
Dr Saia Ma’u Piukala nominated to lead WHO Western Pacific Region

:::::::

WHO - Emergency situation reports

Multi-country outbreak of mpox, External situation report#29 – 20 October 2023

:::::::

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

18 October 2023 | Diphtheria - Guinea

16 October 2023 | Dengue - Chad

:::::::

Weekly Epidemiological Record
https://www.who.int/publications/journals/weekly-epidemiological-record
Vol. 98, No. 41, pp. 489–502
13 October 2023
New WHO Publications
https://www.who.int/publications/i
Selected
20 October 2023
Medication safety for look-alike, sound-alike medicines

20 October 2023
Medication safety for look-alike, sound-alike medicines

19 October 2023
People-centred approach to addressing antimicrobial resistance in human health

17 October 2023
The use of next-generation sequencing for the surveillance of drug-resistant tuberculosis: an implementation...

17 October 2023
Tuberculosis action plan for the WHO European Region, 2023–2030

17 October 2023
Self-care interventions for sexual and reproductive health and rights to advance universal health coverage:...

16 October 2023
WHO Guidelines for malaria

16 October 2023
Joint external evaluation of IHR core capacities of the Kingdom of Thailand: mission report, 31 October-4...

USA – HHS, FDA, CDC

HHS
News
No new digest content identified.

FDA
Press Announcements
FDA Roundup: October 20, 2023
October 20, 2023
... On Thursday, the FDA added 171 devices to the list of artificial intelligence and machine learning (AI/ML)-enabled devices legally marketed in the United States by 510(k) clearance, granted De Novo request, or premarket approval. With this update, the FDA also added insights about trends based on analyses of the data. This list is not meant to be an exhaustive or comprehensive
resource of AI/ML-enabled medical devices. Rather, it is a list of AI/ML-enabled devices across medical disciplines, based on publicly available information. The FDA maintains this list to increase transparency about AI/ML-enabled devices in this rapidly progressing field.

FDA VRBPAC
Advisory Committee Calendar
No new meetings scheduled.

CDC/ACIP [U.S.] [to 21 Oct 2023]
http://www.cdc.gov/media/index.html
Latest News Releases
No new digest content identified.

ACIP Meetings
Next ACIP Meeting
October 25-27.

MMWR Weekly
http://www.cdc.gov/mmwr/index2023.html
October 20, 2023 / No. 42
PDF of this issue
- Preventable Deaths During Widespread Community Hepatitis A Outbreaks — United States, 2016–2022
- Progress Toward Measles and Rubella Elimination — Indonesia, 2013–2022

Europe

European Medicines Agency [EMA]
News & Press Releases
No new digest content identified.

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en
News/Updates/Reports/Publications [Selected]
Scientific and technical publications
Communicable disease threats report, 15-22 October 2023, week 42
Monitoring - 20 Oct 2023

Scientific and technical publications
Evidence-based advice processes for long-term care facilities in the COVID-19 pandemic - Aggregate report from the After-Action reviews in Georgia and Norway
Assessment - 19 Oct 223
**Scientific and technical publications**

**Standard laboratory protocols for SARS-CoV-2 characterisation**
Guidance - 18 Oct 2023

**Scientific and technical publications**

**Evidence-based advice processes for long-term care facilities in the COVID-19 pandemic - Report from the after-action review (AAR) in Norway**
Assessment - 17 Oct 2023

---

**Africa CDC** [to 21 Oct 2023]
http://www.africacdc.org/
Press Releases, Statements [Selected]
Press Releases
**Joint Statement on Action plan to drive equitable expansion of immunisation in Africa**
16 October 2023

---

**China CDC**
http://www.chinacdc.cn/en/

**National Health Commission of the People's Republic of China** [to 21 Oct 2023]
http://en.nhc.gov.cn/
News
No new digest content identified.

**National Medical Products Administration – PRC** [to 21 Oct 2023]
http://english.nmpa.gov.cn/
News
No new digest content identified.

**China CDC Weekly Reports: Current Volume (5)**
2023-10-20 / No. 42

**EPIDEMIOLOGICAL TRANSITION IN INFECTIOUS DISEASES ISSUE**
View PDF of this issue
- Preplanned Studies: Changing Patterns of Mortality in Viral Hepatitis — China, 1987–2021
- Preplanned Studies: Trends and Patterns of Respiratory Tuberculosis Mortality in Rural and Urban — China, 1987–2021
- Perspectives: Epidemiological Shifts in Infectious Diseases in China: Implications and Policy Recommendations

---

**Contents [click to move among sections]**
:: Milestones, Perspectives
:: WHO
Organization Announcements

Paul G. Allen Frontiers Group  [to 21 Oct 2023]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BMGF - Gates Foundation  [to 21 Oct 2023]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute  [to 21 Oct 2023]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
News: Articles and Publications
No new digest content identified.

CARB-X  [to 21 Oct 2023]
https://carb-x.org/
News
No new digest content identified.

CEPI – Coalition for Epidemic Preparedness Innovations  [to 21 Oct 2023]
http://cepi.net/
Latest News
Forecasting viral mutations
Advances in AI are making it possible to quickly and effectively model potential viral vaccine targets
News
20 Oct 2023

Australia’s Doherty Institute joins CEPI’s laboratory network to speed up development of epidemic and pandemic vaccines
Doherty becomes the first laboratory in Australia to join the network, the largest global group set up to standardise testing of vaccine candidates in preclinical and clinical trials.
18 Oct 2023
No new digest content identified.

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 21 Oct 2023]
https://www.darpa.mil/news
News
No new digest content identified.

Duke Global Health Innovation Center [to 21 Oct 2023]
https://dukeghic.org/
News
No new digest content identified.

EDCTP [to 21 Oct 2023]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the
development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS,
tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-
Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center [to 21 Oct 2023]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative [to 21 Oct 2023]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified.

Evidence Aid [to 21 Oct 2023]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the
best available evidence and by championing its use.
http://www.evidenceaid.org/
Resources [Selected]
Health-related disaster communication and social media (research up to 2016)
Added October 19, 2023

Population density and the transmission of COVID-19 and other respiratory viruses
(search done in October 2020)
Added October 17, 2023
**Fondation Merieux** [to 21 Oct 2023]
http://www.fondation-merieux.org/

*News, Events*

**Lessons from COVID-19 vaccine introduction: The current state of behavioral & social determinants of vaccination**
October 30 - November 1, 2023 - Les Pensières, Center for Global Health, Veyrier-du-Lac (France)
The Mérieux Foundation’s Vaccine Acceptance Event Series aims to:
: Establish and maintain dialogue and increase multi-sectoral efforts.
: Promote vaccination acceptance, understand trust bubbles and strengthen the resilience of immunization programs widely affected globally facing important challenges during the pandemic of coronavirus disease 2019, or COVID-19.

**Gavi** [to 21 Oct 2023]
https://www.gavi.org/

*News Releases*
19 October 2023

**Gavi welcomes appointment of global health leader Prof Helen Rees as Chair of Vaccine Investment Strategy Steering Committee**

16 October 2023

**Action plan to drive equitable expansion of immunisation in Africa**

**GE2P2 Global Foundation** [to 21 Oct 2023]
www.ge2p2.org

*News/Analysis/Publications-Digests/Statements*
:: **Vaccines and Global Health: The Week in Review** - Current edition
:: **Informed Consent: A Monthly Review – October 2023**
:: **Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest** – Oct 2023
:: **Public Consultations Watch :: Global Calls for Input/Public Comment – 06 Oct 2023 – Issue 08**

**GHIT Fund** [to 21 Oct 2023]
https://www.ghitfund.org/newsroom/press

*Press Releases*
October 12, 2023

**Global Health Innovative Technology Fund and Institut Pasteur de Dakar Announce New Partnership to Advance Research and Development for New Diagnostics and Vaccines in LMICs**

... Building on their respective expertise and resources, GHIT Fund and IPD will collaborate to foster the development of cutting-edge solutions to combat infectious diseases in Africa and beyond. Through this new partnership, the two institutions will accelerate product development for neglected diseases in LMICs in the areas of therapeutics, vaccine and diagnostic research and development and strengthen collaboration to support low-cost vaccine and diagnostics manufacturing in LMICs through technology transfer and know-how sharing from/with Japanese pharmaceutical companies and academia. This will not only improve access to essential health technologies, but also contribute to the development of a sustainable local health infrastructure...

**Global Fund** [to 21 Oct 2023]
Global Fund and Siemens Healthineers to Accelerate Adoption of Artificial Intelligence for Tuberculosis Diagnosis

Siemens Healthineers and the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund), announced a partnership at the World Health Summit today to accelerate the use of artificial intelligence (AI) in diagnosing tuberculosis (TB), a prev...

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 21 Oct 2023]
https://www.glopid-r.org/news/
News
No new digest content identified.

Hilleman Laboratories [to 21 Oct 2023]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified.

HHMI - Howard Hughes Medical Institute [to 21 Oct 2023]
https://www.hhmi.org/news
Press Room
No new digest content identified.

Human Vaccines Project [to 21 Oct 2023]
http://www.humanvaccinesproject.org/
News
No new digest content identified.

IAVI [to 21 Oct 2023]
https://www.iavi.org/
Latest News, Features
October 13, 2023
Behind the Relentless Pursuit of an HIV Vaccine
Elevating Lab Standards and Embracing Good Clinical Laboratory Practice in Sub-Saharan Africa

INSEM [to 21 Oct 2023]
https://www.inserm.fr/en/home/
Press Releases
No new digest content identified.

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.

ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use  [to 21 Oct 2023]
News/Pubs/Press Releases [Selective]
No new digest content identified.

ICRC  [to 21 Oct 2023]
What's New  [Selected]
Protecting Civilians Against Digital Threats During Armed Conflict
Final report of the ICRC’s Global Advisory Board on Digital Threats During Armed Conflicts. 19-10-2023 | Report

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC  [to 21 Oct 2023]
Press Releases [Selected]
Press release  21/10/2023
IFRC welcomes first aid into Gaza but says much more is needed
Press release  16/10/2023
Humanitarian needs in Sudan grow as funding gap widens, IFRC warns

Institut Pasteur  [to 21 Oct 2023]
Press Documents
No new digest content identified.

ISC / International Science Council  [to 21 Oct 2023]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
News
No new digest content identified.

International Union of Immunological Societies (IUIS)
https://iuis.org/
News/Events [Selected]
2023 International Society for Vaccines (ISV) Annual Congress
Dates: 22 – 24 October 2023
Lausanne, Switzerland

IVAC  [to 21 Oct 2023]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

IVI  [to 21 Oct 2023]
http://www.ivi.int/
IVI News & Announcements
IVI convenes inaugural Global Council meeting in Seoul
October 20, 2023, SEOUL, Republic of Korea — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, held its inaugural Global Council meeting yesterday in Seoul, establishing a new representative body for all IVI State Parties. On the first day of the two-day meeting, country delegates focused discussions on the importance of robust vaccine ecosystems in every part of the world in an era of increasing outbreaks of infectious diseases...

Johns Hopkins Center for Health Security  [to 21 Oct 2023]
https://www.centerforhealthsecurity.org/news/center-news/
Center News [Selected]
October 20, 2023
Center for Health Security submits Senate RFI to reform and strengthen the Centers for Disease Control and Prevention (CDC)
The Johns Hopkins Center for Health Security today provided feedback and suggestions in response to a RFI from Senator Bill Cassidy, on how Congress can help reform and strengthen the CDC.

October 16, 2023
Center for Health Security faculty respond to White House Office of Science and Technology Policy RFI on Dual Use Research of Concern and Potential Pandemic Pathogen Care and Oversight Policy Framework
A group of public health and security experts responded to a Request for Information today from the White House OSTP regarding potential changes to the Policies for Federal and Institutional Oversight of Life Sciences Dual Use Research of Concern (DURC) and Potential Pandemic Pathogen Care and Oversight (P3CO) Policy Framework.

MSF/ Médecins Sans Frontières  [to 21 Oct 2023]
http://www.msf.org/
Latest [Selected Announcements]
Gaza-Israel war
Unconditional humanity needs to be restored in Gaza
Opinion 17 Oct 2023
... Despite the incredible needs, the widespread bombing and the impossibility to bring in supplies has forced us to suspend most of our activities. Our teams inside and outside of Gaza are doing the best they can to respond.
As a medical and humanitarian organisation, we want to do so much more. Today this is just impossible.

**National Academy of Medicine** - USA  [to 21 Oct 2023]
https://nam.edu/programs/
*News [Selected]*
**Statement by NAM President Victor Dzau on Humanitarian Crisis in Israel and Gaza**
October 19, 2023

**National Academy of Sciences** - USA  [to 21 Oct 2023]
https://www.nationalacademies.org/newsroom?
*News*
*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS  [to 21 Oct 2023]
https://www.hhs.gov/vaccines/about/index.html
*Upcoming Meetings/Latest Updates*
*No new digest content identified.*

**NIH**  [to 21 Oct 2023]
http://www.nih.gov/
*News Releases*
*No new digest content identified.*

**PATH**  [to 21 Oct 2023]
https://www.path.org/media-center/
*Press Releases*
**Join PATH at the 2023 American Society of Tropical Medicine and Hygiene Annual Meeting**
PATH will join partners from around the world to exchange the latest research at this annual gathering of tropical medicine and global health professionals. This year’s meeting will be held in Chicago from October 18-22.

**Rockefeller Foundation**  [to 21 Oct 2023]
https://www.rockefellerfoundation.org/
*Selected Reports/Press Releases*
*No new digest content identified.*

**Sabin Vaccine Institute**  [to 21 Oct 2023]
https://www.sabin.org/press/
*Latest News & Press Releases*
*Press Releases*
**Sabin Vaccine Institute Begins Phase 2 Clinical Trial for Marburg Vaccine in Uganda**
October 19, 2023
...Healthy volunteers received the single-dose vaccine at Makerere University Walter Reed Project (MUWRP) in Kampala, Uganda today...

UNAIDS [to 21 Oct 2023]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
No new digest content identified.

UNICEF [to 21 Oct 2023]
https://www.unicef.org/media/press-releases
Latest press releases, news notes and statements
Statement 21 October 2023
Joint statement by UNDP, UNFPA, UNICEF, WFP and WHO on humanitarian supplies crossing into Gaza
NEW YORK/GENEVA/ROME, 21 October 2023 – “A first, but limited, shipment of life-saving humanitarian supplies from the United Nations and the Egyptian Red Crescent entered Gaza today on 20 trucks, passing through the Rafah Crossing. “It will provide an urgently needed lifeline to some of the hundreds of thousands of civilians, mostly women and...

Unitaid [to 21 Oct 2023]
https://unitaid.org/
Featured News
No new digest content identified.

Vaccine Equity Cooperative [nee Initiative] [to 21 Oct 2023]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

Vaccination Acceptance & Demand Initiative [Sabin] [to 21 Oct 2023]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.

Vaccine Confidence Project [to 21 Oct 2023]
http://www.vaccineconfidence.org/
News, Research and Reports
No new digest content identified.

Vaccine Education Center – Children’s Hospital of Philadelphia [to 21 Oct 2023]
http://www.chop.edu/centers-programs/vaccine-education-center
News
Fall 2023 Vaccines: Considering Flu, COVID-19 and RSV
Oct 1, 2023

For the first time, vaccines are available to prevent three typical winter respiratory viruses: influenza, COVID-19 and RSV. In this short video, Dr. Offit talks about the vaccines that protect against each of these viruses and who should get them.

**Wellcome Trust** [to 21 Oct 2023]
https://wellcome.ac.uk/news
News. Opinion, Reports
No new digest content identified.

**The Wistar Institute** [to 21 Oct 2023]
Press Releases
Press Release Oct. 17, 2023
Dean Stoios Joins The Wistar Institute as Chief Financial Officer
PHILADELPHIA (October 17, 2023) – The Wistar Institute, a global leader in biomedical research in cancer, immunology and infectious diseases, announces the appointment of Dean Stoios as Chief Financial Officer.

**World Bank** [to 015 Oct 2022]
All News [Selected]
Ending Poverty is our First Global Goal, and We are Off Track
We are at a critical juncture today in the fight against poverty. Despite decades of hard-won development progress, a world free of poverty remains out of sight. Ten years ago, the outlook appeared more...
Date: October 17, 2023 Type: Opinion

**WFPHA: World Federation of Public Health Associations** [to 21 Oct 2023]
https://www.wfpha.org/
Latest News - Blog
No new digest content identified.

**World Medical Association [WMA]** [to 21 Oct 2023]
Press Releases
The World Medical Association stands firmly for the principles of medical neutrality as defined by the Geneva Convention, and calls on all parties to respect International Law and the integrity of unrelated civilian populations
15.10/2023

**World Organisation for Animal Health** [to 21 Oct 2023]
https://www.oie.int/en/
Press Releases, Statements
Statements
African swine fever: WOAH warns Veterinary Authorities and pig industry of risk from use of sub-standard vaccines
18 Oct 2023

In this context, the World Organisation for Animal Health (WOAH) stresses the importance of the use of only high-quality ASF vaccines with proven efficacy and safety, and which have been subject to regulatory evaluation and approval in accordance with WOAH international standards...

::::

ARM [Alliance for Regenerative Medicine]  [to 21 Oct 2023]
Selected Press Releases
No new digest content identified.

BIO  [to 21 Oct 2023]
Press Releases
New USITC report shows "no credible evidence" supporting a TRIPs waiver expansion
October 17, 2023

The United States International Trade Commission (USITC) today released its “COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities” report. The report aims to analyze various issues and information gaps concerning...

DCVMN – Developing Country Vaccine Manufacturers Network  [to 21 Oct 2023]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations  [to 21 Oct 2023]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA  [to 21 Oct 2023]
https://ifpma.org/
Selected Press Releases/Statements
Statement 18 Oct 2023
IFPMA statement at the 74th Session of the WHO Regional Committee for the Western Pacific
On 18 October 2023 at the 74th Session of the WHO Regional Committee for the Western Pacific in Manila, Philippines, IFPMA submitted a statement on agenda item 11: Health security.

Statement 17 Oct 2023
IFPMA Statement at the WIPO Standing Committee on the Law of Patents (SCP) 35
On 17 October in Geneva, IFPMA submitted a statement at the WIPO Standing Committee on the Law of Patents (SCP) 35.

Statement 17 Oct 2023
Innovative pharmaceutical industry statement on draft WHO Pandemic Treaty: We need to preserve what went well and address what went wrong

On 16 October 2023, IFPMA issued a statement in response to draft WHO Pandemic Treaty.

External study 16 Oct 2023
The value of vaccines to mitigate antimicrobial resistance
A report published by One Health Trust makes an urgent call for increasing vaccination coverage to tackle the growing threat of antimicrobial resistance (AMR) in low- and middle-income countries.

International Alliance of Patients’ Organizations – IAPO  [to 21 Oct 2023]  
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]  
No new digest announcements identified

International Generic and Biosimilar Medicines Association [IGBA]  
https://www.igbamedicines.org/  
News  
No new digest announcements identified

PhRMA  [to 21 Oct 2023]  
http://www.phrma.org/  
Press Releases  
WASHINGTON, D.C. (October 17, 2023) – Today, Pharmaceutical Research and Manufacturers of America (PhRMA) Deputy Vice President for Public Affairs Megan Van Etten issued the following statement in response to the U.S. International Trade Commission (USITC) report on “COVID-19 Diagnostics and Therapeutics: Supply, Demand, and TRIPS Agreement Flexibilities:”

“The COVID-19 public health emergency is over and across the world there is an abundance of affordable and often free treatments. TRIPS waiver expansion is unnecessary and would harm American workers, patients and innovation by handing over IP to foreign competitors. It’s past time for the Biden administration and other world leaders to move beyond this ideological debate and focus on real global health challenges.”...

::::
::::

Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements

AstraZeneca  
Press Releases - No new digest announcements identified

Bharat Biotech  
Press Releases - No new digest announcements identified

BioCubaFarma – Cuba  
Últimas Noticias - Website not responding at inquiry

Biological E
BioNTech
Press Releases
19 October 2023
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Boehringer
Press Releases - No new digest announcements identified

CanSinoBIO
News - Website not responding at inquiry

CIGB
Latest News - No new digest announcements identified

Cinnagen
Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac [Bayer Ag – Germany]
News - No new digest announcements identified

Gamaleya National Center/Sputnik
Latest News and Events - No new digest announcements identified
https://sputnikvaccine.com/ - No new digest announcements identified

GSK
Press releases for media
18 October 2023
ViiV Healthcare to present 23 abstracts from innovative HIV treatment and prevention portfolio at EACS 2023
  Key data to be presented include long-term and real-world data, including long-acting and 2-drug regimens.

IMBCAMS, China
Home - Website not responding at inquiry

Janssen/JNJ
Press Releases - No new digest announcements identified

Merck
News releases - No new digest announcements identified

Moderna
Press Releases - No new digest announcements identified

Nanogen
Novartis
News
- No new digest announcements identified

Novavax
Press Releases
Oct 18, 2023  COVID-19
Novavax Receives Full Marketing Authorization for Prototype COVID-19 Vaccine Nuvaxovid™ ▼ in United Kingdom

Oct 18, 2023  COVID-19
Novavax’s Prototype COVID-19 Vaccine Nuvaxovid™ Receives Full Approval in Singapore

Oct 16, 2023  Statement COVID-19
Novavax Statement on 2023-2024 COVID-19 Vaccination Season

Pfizer
Recent Press Releases
10.20.2023
FDA Approves PENBRAYA™, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
:: PENBRAYA™ provides the broadest serogroup coverage (meningococcal groups A, B, C, W and Y) of any meningococcal vaccine available in the U.S. and has the potential to help simplify complex vaccination schedule in the U.S.
:: The FDA’s decision is based on data from Phase 2 and Phase 3 trials, which demonstrated that PENBRAYA has robust immunogenicity non-inferior to Trumenba® + Menevo® for all serogroups and was well-tolerated with a favorable safety profile
:: The vaccine further advances Pfizer’s vaccine portfolio and builds on more than 20 years of expertise and knowledge in the prevention of meningococcal disease

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases
Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
Paris, October 19, 2023. Sanofi has delivered the first medicines from its Global Health Unit’s not-for-profit Impact brand portfolio to the Republic of Djibouti. Enoxaparin Sodium Impact is an anticoagulant medicine indicated for the treatment of venous thromboembolism including deep vein thrombosis, a potentially lethal disease often underdiagnosed on the African continent. With this first shipment to Djibouti, Sanofi delivers on its commitment to improve and accelerate affordable and sustainable access to quality medicines, vaccines and healthcare for underserved populations...

Serum Institute of India
NEWS & ANNOUNCEMENTS  - No new digest announcements identified

Sinopharm/WIBPBIBP
Sinovac
Press Releases
**SINOVAC's Vital Role in the Belt and Road Initiative: A Lifeline in the Fight Against Infectious Diseases**
2023-10-20
October 20, 2023, Beijing, China – Sinovac Biotech Ltd. ("SINOVAC" or the "Company") (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today shared its accomplishments in collaboration with the Belt and Road Initiative (BRI) countries, demonstrating its commitment to the initiative's guiding principle of "planning together, building together, and benefiting together."
SINOVAC has provided over 1.2 billion doses of vaccines to 62 BRI countries, offering protection against a range of infectious diseases such as COVID-19, hepatitis A, influenza and varicella, as well as pneumococcal infections.
Behind these remarkable figures are 20 research projects in 10 BRI countries, 95 marketing approvals and emergency use authorizations, 17 technology licensing agreements for vaccine production signed in 12 BRI countries, and localized production programs in seven...

SK Biosciences
Press Releases
**Updated Novavax COVID-19 Vaccine Is Submitted for Emergency Use Authorization in the Republic of Korea**
SK bioscience plans to introduce the only updated protein-based non-mRNA, COVID vaccine for South Ko...
2023.10.20

Takeda
Newsroom - No new digest announcements identified

Valneva
Press Releases - No new digest announcements identified

Vector State Research Centre of Viralology and Biotechnology
Home - Website not responding [404 error]

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]
Journal Watch

Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 14, 2023 Issue 3
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 25, Number 10: E719-790
https://journalofethics.ama-assn.org/issue/geriatric-psychiatry

Geriatric Psychiatry
Twenty percent of the US population is expected to be 65 years of age or older by 2030. Ageism’s pervasiveness in US culture means it is also pervasive in health care and a cause of inequity that profoundly undermines older adults’ quality of life. Independence and autonomy losses tend to accompany aging for all of us. Older adults are vulnerable to exploitation and are exposed to late-life stressors that affect their mental health, accompany compromise or loss of independence and autonomy, and tend to track declines in general health and cognitive function. This theme issue investigates reasons why diminishing numbers of geriatric mental health clinicians should draw clinical, ethical, and legal attention to whether and how well US health care and its workforce is prepared to deliver the volume and quality of care older adults deserve.

American Journal of Human Genetics
Oct 05, 2023 Volume 110 Issue 10 p1607-1826
https://www.cell.com/ajhg/current
[Reviewed earlier]

American Journal of Infection Control
October 2023 Volume 51 Issue 10 p1083-1200
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
October 2023 Volume 65 Issue 4 p551-762
https://www.ajpmonline.org/current
[Reviewed earlier]
More Protection Against Respiratory Viral Infection: Respiratory Syncytial Virus Vaccines for Adults Aged 60 Years and Older
Camille Nelson Kotton, MD
Pages: 1419–1421
Understanding multilevel barriers to childhood vaccination uptake among Internally Displaced Populations (IDPs) in Mogadishu, Somalia: a qualitative study

Disparities in vaccination coverage exist in Somalia with Internally Displaced Persons (IDPs) being among the groups with the lowest coverage. We implemented an adapted Participatory Learning and Action (PLA) ...

Authors: Mohamed Jelle, Andrew J Seal, Hodan Mohamed, Hani Mohamed, Mohamed Sheikh Omar, Sadik Mohamed, Amina Mohamed and Joanna Morrison

Citation: BMC Public Health 2023 23:2018

Content type: Research Published on: 17 October 2023
**Immunogenicity, safety, usability and acceptability of microarray patches for vaccination: a systematic review and meta-analysis** (12 October, 2023)
Matthew N Berger, Ellen S Mowbray, Marian W A Farag, Erin Mathieu, Cristyn Davies, Claire Thomas, Robert Booy, Angus H Forster, S Rachel Skinner

**Performance of predictive algorithms in estimating the risk of being a zero-dose child in India, Mali and Nigeria** (11 October, 2023)
Arpita Biswas, John Tucker, Sebastian Bauhoff

**Trends in public health emergencies in the WHO African Region: an analysis of the past two decades public health events from 2001 to 2022** (9 October, 2023)
Etien Luc Koua, Jobert Richie Nansseu Njingang, Jean Paul Kimenyi, George Sie Williams, Joseph Okeibunor, Sakuya Oka, Abdou Salam Gueye

**A critical analysis of COVAX alliance and corresponding global health governance and policy issues: a scoping review** (4 October, 2023)
Anjali Pushkaran, Vijay Kumar Chattu, Prakash Narayanan

**Bulletin of the Atomic Scientists**
September 2023
https://thebulletin.org/magazine/2023-09/

*Contents*
[Reviewed earlier]

**Bulletin of the World Health Organization**
Volume 101(10); 2023 Oct 1
https://www.ncbi.nlm.nih.gov/pmc/issues/446112/
[Reviewed earlier]

**Cell**
Oct 12, 2023 Volume 186 Issue 21 p4475-4728
https://www.cell.com/cell/current
[New issue; No digest content identified]

**Child Care, Health and Development**
Volume 49, Issue 6 Pages: 941-1111 November 2023
https://onlinelibrary.wiley.com/toc/13652214/current
[New issue; No digest content identified]

**Clinical Pharmacology & Therapeutics**
Volume 114, Issue 4 Pages: 723-932 October 2023
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[Reviewed earlier]

**Clinical Therapeutics**
September 2023 Volume 45 Issue 9 p807-924
Clinical Trials
Volume 20 Issue 5, October 2023
https://journals.sagepub.com/toc/ctja/20/5
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 21 Oct 2023]
[No new digest content identified]

Contemporary Clinical Trials
Volume 133 October 2023
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/133/suppl/C
Research article Abstract only
Developing and testing a COVID-19 vaccination acceptance intervention: A pragmatic trial comparing vaccine acceptance intervention vs usual care – Rationale, methods, and implementation
Jeffrey M. Pyne, Karen H. Seal, Jennifer K. Manuel, Beth DeRonne, ... A. Rani Elwy
Article 107325

The CRISPR Journal
Volume 6, Issue 5 / October 2023
https://www.liebertpub.com/toc/crispr/6/5
[New issue; No digest content identified]

Current Genetic Medicine Reports
Volume 10, issue 3, September 2022
https://link.springer.com/journal/40142/volumes-and-issues/10-3
[Reviewed earlier]

Current Medical Research and Opinion
Volume 39, Issue 10 2023
https://www.tandfonline.com/toc/icmo20/current
Review Article
Bioethics of somatic gene therapy: what do we know so far?
Paola Buedo, Alahi Bianchini, Katarzyna Klas & Marcin Waligora
Pages: 1355-1365
Published online: 10 Oct 2023

Current Opinion in Infectious Diseases
October 2023 - Volume 36 - Issue 5
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
Current Protocols in Human Genetics
https://currentprotocols.onlinelibrary.wiley.com/journal/19348258
[Accessed 21 Oct 2023]
[No new digest content identified]

Developing World Bioethics
Volume 23, Issue 3 Pages: 197-292 September 2023
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 33, Issue 7, 2023
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Development Policy Review
Volume 41, Issue 5 September 2023
https://onlinelibrary.wiley.com/toc/14677679/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 6 - December 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 47, Issue 3 Pages: 543-846 July 2023
[Reviewed earlier]

EMBO Reports
Volume 24 Issue 10 9 October 2023
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 29, Number 10—October 2023
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]
Epidemics
Volume 44  September 2023
https://www.sciencedirect.com/journal/epidemics/vol/44/suppl/C
[Reviewed earlier]

Epidemiology and Infection
Volume 151 - 2023
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]

Ethics & Human Research
Volume 45, Issue 5 Pages: 1-47  September–October 2023
https://onlinelibrary.wiley.com/toc/25782363/current
Adaptive clinical trials :: Deprioritizing ongoing clinical trials
[Reviewed earlier]

Ethics & International Affairs
Volume 37 - Issue 2 - Summer 2023
https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 30  October 2023
[Reviewed earlier]

The European Journal of Public Health
Volume 33, Issue 5, October 2023
https://academic.oup.com/eurpub/issue/33/5
[Reviewed earlier]

Expert Review of Vaccines
Vol 22 (1) 2023
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
September/October 2023  Volume 102, Number 5
https://www.foreignaffairs.com/issues/2023/102/5
[Reviewed earlier]

Forum for Development Studies
Volume 50, 2023 - Issue 3
http://www.tandfonline.com/toc/sfds20/current
The papers in this special section work together to move toward a global social medicine for the 22nd century. They envision a global social medicine that confronts and moves beyond the
traditionally colonial, xenophobic, heteronormative, patriarchal, gender-binary-bound, capitalist, and racist histories of the fields of global health and human rights. They seek to instantiate a global social medicine that centers knowledge and experiences from the Global South and works toward social justice and health equity at scale. In this special section, the authors are particularly interested in understanding, challenging, and expanding our perspectives and enactments of the right to health. Unlike neoliberal perspectives on health that often limit their explanatory capacity to how individuals behave in the world, the papers here move beyond the focus on lifestyles and on the phantasmagoria of a sovereign subject with supposedly free agency. Instead, authors work toward critical consciousness that accounts for structural processes—with their inequities and disruptions, as well as their effects on individuals—and how this consciousness can open new horizons for collective transformation and social emancipation in health...

Health Economics, Policy and Law
Volume 18 - Special Issue 4 - October 2023
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
SPECIAL ISSUE: On the roof top of health policy change
[Reviewed earlier]

Health Policy and Planning
Volume 38, Issue 8, October 2023
https://academic.oup.com/heapol/issue/38/8
[Reviewed earlier]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 21 Oct 2023]
[No new digest content identified]

Human Gene Therapy
Volume 34, Issue 17-18 / September 2023
https://www.liebertpub.com/toc/hum/34/17-18
[Reviewed earlier]

Humanitarian Practice Network
https://odihpn.org/
Featured Publications
[No new digest content identified]

Human Vaccines & Immunotherapeutics (formerly Human Vaccines)
Volume 19, Issue 3, 2023
https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList
[Reviewed earlier]

Immunity
Oct 10, 2023  Volume 56  Issue 10  p2177-2456
Accelerating into Immunization Agenda 2030 with momentum from China’s successful COVID-19 vaccination campaign during dynamic COVID Zero

China's immunization programs conducted a unified, tightly coordinated COVID-19 vaccination campaign during the dynamic COVID Zero period that reached well over 90% of the population with vaccines having > 90%...

Authors: Lance E. Rodewald

Citation: Infectious Diseases of Poverty 2023 12:96
Content type: Commentary Published on: 16 October 2023
Journal of Development Economics
Volume 165  October 2023
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 18 Issue 4, October 2023
http://journals.sagepub.com/toc/jre/current
Ethical Issues in Research in Low and Middle-Income Countries
[Reviewed earlier]

Journal of Epidemiology & Community Health
September 2023 - Volume 77 - 9
https://jech.bmj.com/content/77/9
[Reviewed earlier]

Journal of Evidence-Based Medicine
Volume 16, Issue 3  Pages: 259-413  September 2023
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 19, Issue 2 (2023)
http://www.tandfonline.com/toc/rjge20/current
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 34, Number 3, August 2023
https://muse.jhu.edu/issue/50808
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 25, issue 5, October 2023
[Reviewed earlier]

Journal of Immigrant & Refugee Studies
Volume 21, 2023 _ Issue 3
https://www.tandfonline.com/toc/wimm20/current
[Reviewed earlier]
Journal of Infectious Diseases
Volume 228, Issue 5, 1 September 2023
https://academic.oup.com/jid/issue/228/5
[Reviewed earlier]

Journal of International Development
Volume 35, Issue 7 Pages: 1549-2249 October 2023
https://onlinelibrary.wiley.com/toc/10991328/current
[New issue; No digest content identified]

Journal of Medical Ethics
October 2023 - Volume 49 - 10
http://jme.bmj.com/content/current
[Reviewed earlier]

Journal of Patient-Centered Research and Reviews
Volume 10, Issue 3 (2023)
https://institutionalrepository.aah.org/jpcrr/
[New issue; No digest content identified]

The Journal of Pediatrics
Volume 261, October 2023
[Reviewed earlier]

Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 21 Oct 2023]
[No new digest content identified]

Journal of Public Health Management & Practice
September/October 2023 - Volume 29 - Issue 5
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 44, issue 3, September 2023
https://link.springer.com/journal/41271/volumes-and-issues/44-3
[Reviewed earlier]

Journal of the Royal Society – Interface
October 2023 Volume 20 Issue 207
https://royalsocietypublishing.org/toc/rsif/current
Review

**Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis**

Michael Reid, get al.

The 2019 Lancet Commission on Tuberculosis laid out an optimistic vision for how to build a tuberculosis-free world through smart investments based on sound science and shared responsibility. Since then, several major strides have been made towards ending tuberculosis, including substantive improvements in treatment outcomes for people with drug-resistant disease. Although COVID-19 has undermined global progress, many African countries have sustained declines in tuberculosis mortality rates. With excellent short-course preventive regimens and several late-stage vaccine candidates, tuberculosis prevention is also on the cusp of a revolution. Still, much more can be done to fully implement the Commission's recommendations (panel 1) and realise the ambitious targets set out at the UN High-Level Meeting (HLM) on tuberculosis in 2018. In the 5 years since the HLM, more than 7 million people have died of tuberculosis; their deaths are a profound tragedy and a reminder of the urgency of accelerating momentum.

Editorial

**Child poverty in 2023: inequity in times of crises**

The Lancet Child & Adolescent Health

... While lifting children out of poverty remains a key priority, it is also important to prevent vulnerable households from tipping, or sliding back, into poverty. WHO estimates that out-of-pocket spending on health pushes 100 million people into extreme poverty each year, and universal health coverage is therefore an essential component of reducing child poverty. Ensuring access to high-quality health care, early child development programmes, education, and social protection is foundational to breaking the insidious cycle of poverty. Having witnessed how severely a global pandemic can compound vulnerability to poverty, it is necessary that these systems and programmes are resilient to severe shocks in the future.

Worldwide, paediatricians have a crucial role in supporting children and families in coping with the health burden of poverty and referring them to relevant services. But individual-level efforts are
uphill battles when surrounding systems are inherently inequitable. When, for example, a fully vaccinated, breastfeeding child is malnourished because the family does not have enough food or secure housing, there is little that individual paediatricians can do. It is incumbent on all sectors of society to unify towards liberating resources for households and supporting children's social mobility out of poverty. This starts by governments placing children at the heart of all policies and investing in the programmes that will see child poverty, in all its dimensions, tackled.

Review
The evolving treatment landscape for children with sickle cell disease
Seethal A Jacob, Ravi Talati, Julie Kanter
Summary
Sickle cell disease is the most common inherited pathological haemoglobinopathy. Over the past 30 years, disease-related morbidity and mortality have improved in high-income countries due to advances in preventive care and treatments. Established disease-modifying therapies, such as hydroxyurea (hydrocarbamide), are continuing to have an important role in the treatment of sickle cell disease, and newer agents also show promise. In the past 5 years, the US Food and Drug Administration approved three additional sickle cell disease-modifying medications, and new gene therapies have been developed as an alternative curative treatment to haematopoietic stem-cell transplantation. In this Review, we discuss the current treatment landscape for paediatric sickle cell disease and emerging innovations in care. We also review the need for close, long-term management for children receiving newer therapies and the importance of ongoing investment in people with sickle cell disease in low-income and middle-income countries.

Lancet Digital Health
Oct 2023 Volume 5 Number 10  e632-e748
https://www.thelancet.com/journals/landig/issue/current
Review
FAIR, ethical, and coordinated data sharing for COVID-19 response: a scoping review and cross-sectional survey of COVID-19 data sharing platforms and registries
Lauren Maxwell, et al.
Summary
Data sharing is central to the rapid translation of research into advances in clinical medicine and public health practice. In the context of COVID-19, there has been a rush to share data marked by an explosion of population-specific and discipline-specific resources for collecting, curating, and disseminating participant-level data. We conducted a scoping review and cross-sectional survey to identify and describe COVID-19-related platforms and registries that harmonise and share participant-level clinical, omics (eg, genomic and metabolomic data), imaging data, and metadata. We assess how these initiatives map to the best practices for the ethical and equitable management of data and the findable, accessible, interoperable, and reusable (FAIR) principles for data resources. We review gaps and redundancies in COVID-19 data-sharing efforts and provide recommendations to build on existing synergies that align with frameworks for effective and equitable data reuse. We identified 44 COVID-19-related registries and 20 platforms from the scoping review. Data-sharing resources were concentrated in high-income countries and siloed by comorbidity, body system, and data type. Resources for harmonising and sharing clinical data were less likely to implement FAIR principles than those sharing omics or imaging data. Our findings are that more data sharing does not equate to better data sharing, and the semantic and technical interoperability of platforms and registries harmonising and sharing COVID-19-related participant-level data needs to improve to facilitate the global collaboration required to address the COVID-19 crisis.

Health Policy
Mapping and evaluating national data flows: transparency, privacy, and guiding infrastructural transformation
Joe Zhang, et al.

Summary
The importance of big health data is recognised worldwide. Most UK National Health Service (NHS) care interactions are recorded in electronic health records, resulting in an unmatched potential for population-level datasets. However, policy reviews have highlighted challenges from a complex data-sharing landscape relating to transparency, privacy, and analysis capabilities. In response, we used public information sources to map all electronic patient data flows across England, from providers to more than 460 subsequent academic, commercial, and public data consumers. Although NHS data support a global research ecosystem, we found that multistage data flow chains limit transparency and risk public trust, most data interactions do not fulfil recommended best practices for safe data access, and existing infrastructure produces aggregation of duplicate data assets, thus limiting diversity of data and added value to end users. We provide recommendations to support data infrastructure transformation and have produced a website (https://DataInsights.uk) to promote transparency and showcase NHS data assets.

Lancet Global Health
Nov 2023 Volume 11 Number 11 e1667-e1826
https://www.thelancet.com/journals/langlo/issue/current

Articles
Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone
Edward Man-Lik Choi, et al. for the EBOVAC-3/EBL2005 Study Team

Review
The effect and control of malaria in pregnancy and lactating women in the Asia-Pacific region
Holger W Unger, et al.

Health Policy
Clinical and regulatory development strategies for Shigella vaccines intended for children younger than 5 years in low-income and middle-income countries
Birgitte K Giersing, et al.

Lancet Infectious Diseases
Oct 2023 Volume 23 Number 10 p1095-1206, e390-e454
https://www.thelancet.com/journals/laninf/issue/current

Editorial
Can we control dengue?
The Lancet Infectious Diseases

Articles
Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study
Dan Yamin, et al.
Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial
Jing-Xin Li, et al. for the Six-Province COVID-19 Vaccine Study Group

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial

Safety and immunogenicity of a novel multivalent OspA-based vaccine candidate against Lyme borreliosis: a randomised, phase 1 study in healthy adults
Nicole Bézay, et al.

Lancet Public Health
Oct 2023 Volume 8 Number 10 e743-e826
https://www.thelancet.com/journals/lanpub/issue/current

Articles

Potential population-level effectiveness of one-dose HPV vaccination in low-income and middle-income countries: a mathematical modelling analysis
Élodie Bénard, et al.

Lancet Respiratory Medicine
Oct 2023 Volume 11 Number 10 p851-944, e84-e88
https://www.thelancet.com/journals/lanres/issue/current
[New issue; No digest content identified]

Maternal and Child Health Journal
Volume 27, issue 9, September 2023
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 43 Issue 6, August 2023
http://mdm.sagepub.com/content/current
[Reviewed earlier]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 101, Issue 3 Pages: 637-998 September 2023
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]

Molecular Therapy
Oct 04, 2023 Volume 31 Issue 10 p2813-3104
https://www.cell.com/molecular-therapy/current
How to share data — not just equally, but equitably

Just as with many natural resources, wealthy countries have been extracting scientific data from poorer nations for centuries. Researchers are changing that.
Open Science 2.0: Towards a truly collaborative research ecosystem
Robert T. Thibault, Olavo B. Amaral, Felipe Argolo, Anita E. Bandrowski, Alexandra R, Davidson, Natascha I. Drude
Essay | published 19 Oct 2023 PLOS Biology
https://doi.org/10.1371/journal.pbio.3002362

Abstract
Conversations about open science have reached the mainstream, yet many open science practices such as data sharing remain uncommon. Our efforts towards openness therefore need to increase in scale and aim for a more ambitious target. We need an ecosystem not only where research outputs are openly shared but also in which transparency permeates the research process from the start and lends itself to more rigorous and collaborative research. To support this vision, this Essay provides an overview of a selection of open science initiatives from the past 2 decades, focusing on methods transparency, scholarly communication, team science, and research culture, and speculates about what the future of open science could look like. It then draws on these examples to provide recommendations for how funders, institutions, journals, regulators, and other stakeholders can create an environment that is ripe for improvement.
Review

Global regulatory reforms to promote equitable vaccine access in the next pandemic

Richard Mahoney, Peter J. Hotez, Maria Elena Bottazzi
| published 18 Oct 2023 PLOS Global Public Health
https://doi.org/10.1371/journal.pgph.0002482

Abstract

There is broad consensus that the global response to the Covid-19 pandemic was inadequate, leading to unacceptable levels of avoidable morbidity and mortality. Three strategic missteps led to the lack of equitable vaccine access: The heavy reliance on commercial vaccine manufacturers in high-income countries (HICs) versus low- and middle-income countries (LMICs); the emergence of vaccine nationalism restricting and delaying the supply of vaccines to LMICs; and an inadequate support or recognition for LMIC national regulatory authorities. To avoid these inequities in a future pandemic, we focus on three successful vaccine development and technology transfer case studies—the Hepatitis B vaccine produced in South Korea in the 1980s; the Meningitis A vaccine for Africa led by Program for Appropriate Technologies in Health (PATH) and the World Health Organization (WHO) in the 2000s; and a recombinant SARS CoV-2 protein-based vaccine technology from the Texas Children’s Hospital transferred to India and to Indonesia. In addition to expanding support for academic or non-profit product development partnerships, our analysis finds that an essential step is the strengthening of selected LMIC regulatory systems to become Stringent Regulatory Authorities (SRAs), together with a re-prioritization of the WHO Prequalification (PQ) system to ensure early vaccine availability in LMICs especially during pandemics. Advancing LMIC National Regulatory Authorities (NRAs) to Stringent Regulatory Authorities (SRAs) status will require substantial resources, but the benefits for future pandemic control and for health in LMIC would be immense. We call on the WHO, United Nation (UN) agencies and SRAs, to collaborate and implement a comprehensive roadmap to support LMIC regulators to achieve stringent status by 2030.
Post-epidemic health system recovery: A comparative case study analysis of routine immunization programs in the Republics of Haiti and Liberia
Sanjana J. Ravi, Christina M. Potter, Ligia Paina, Maria W. Merritt
Research Article | published 17 Oct 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0292793

Poor reporting quality of randomized controlled trials comparing treatments of COVID-19–A retrospective cross-sectional study on the first year of publications
Linda Grüßer, Charlotte Eißing, Ana Kowark, András P. Keszei, Julia Wallqvist, Rolf Rossaint, Sebastian Ziemann
Research Article | published 16 Oct 2023 PLOS ONE
https://doi.org/10.1371/journal.pone.0292860

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 21 Oct 2023]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
October 17, 2023 | vol. 120 | no. 42
https://www.pnas.org/toc/pnas/120/42
[New issue; No digest content identified]

PNAS Nexus
Volume 2, Issue 9, September 2023
https://academic.oup.com/pnasnexus/issue/2/9
[Reviewed earlier]

Prehospital & Disaster Medicine
Volume 38 - Issue 5 - October 2023
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 174 September 2023
[Reviewed earlier]

Proceedings of the Royal Society B
25 October 2023 Volume 290 Issue 2009
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Public Health
**Risk Management and Healthcare Policy**
[Accessed 21 Oct 2023]
[Reviewed earlier]

**Science**
Volume 382| Issue 6668| 20 Oct 2023
https://www.science.org/toc/science/current
*Editorial*
**Safeguard the world’s worst pathogens**
BY Piers Millett
19 Oct 2023: 243

**Science and Engineering Ethics**
Volume 29, issue 5, October 2023
[Reviewed earlier]

**Science Translational Medicine**
Volume 15| Issue 718| 18 Oct 2023
https://www.science.org/toc/stm/current
*Special issue: Zoonotic diseases*
*Editorial*
**What keeps me up at night**
BY Anthony S. Fauci
18 Oct 2023
The lessons of COVID-19 must be heeded if the world is to be prepared for the next emergent pathogen with pandemic potential.

*Viewpoints*
**Drug discovery in Africa tackles zoonotic and related infections**
BY Christabel N. Hikaambo, et al.
18 Oct 2023
African drug discovery scientists are making headway in addressing the burden of zoonotic and related infections on their continent.

**Many potential pathways to future pandemic influenza**
BY David M. Morens, Jaekeun Park, Jeffery K. Taubenberger
18 Oct 2023
Influenza pandemics have emerged for centuries but still cannot be accurately predicted.

**Zoonotic mosquito-borne arboviruses: Spillover, spillback, and realistic mitigation strategies**
BY Rafael K. Campos, Shannan L. Rossi, Robert B. Tesh, Scott C. Weaver
18 Oct 2023
Mosquito-borne viruses increasingly threaten human health, requiring enhanced surveillance, prevention, and treatment strategies to prevent outbreaks.
A ticking time bomb hidden in plain sight
BY Sukanya Narasimhan, et al.
18 Oct 2023
It is time for a One Health approach to address the rising threat of tick-borne diseases.

Wastewater surveillance facilitates climate change–resilient pathogen monitoring
BY Megan B. Diamond, et al.
18 Oct 2023
Wastewater surveillance data can inform how climate change impacts pathogen dynamics and guide stronger public health intervention strategies

Scientific Reports
https://www.nature.com/srep/articles?type=article
[Accessed 21 Oct 2023]
[No new digest content identified]

Social Science & Medicine
Volume 332  September 2023
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 21 Oct 2023]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 44, issue 5, October 2023
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Travel Medicine and Infectious Diseases
Volume 55  September–October 2023
[Reviewed earlier]

Tropical Medicine & International Health
Volume 28, Issue 10  Pages: i-iv, 797-838  October 2023
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 41, Issue 45  Pages 6625-6774 (26 October 2023)
https://www.sciencedirect.com/journal/vaccine/vol/41/issue/45
“The problem is not lack of information”: A qualitative study of parents and school nurses’ perceptions of barriers and potential solutions for HPV vaccination in schools
Maude Dionne, Chantal Sauvageau, Marilou Kiely, Mika Rathwell, ... Ève Dubé
Pages 6654-6660

Exploring factors that influence vaccination uptake for children with refugee backgrounds: An interpretive description study of primary healthcare providers’ perspectives
Larisa Cavit, Nadia A. Charania
Pages 6690-6699

How to increase and maintain high immunization coverage: Vaccination Demand Resilience (VDR) framework
Sachiko Ozawa, Holly B. Schuh, Tomoka Nakamura, Tatenda T. Yemeke, ... Noni E. MacDonald
Pages 6710-6718

Stakeholders’ Understanding of European Medicine Agency’s COVID-19 Vaccine Information Materials in EU and Regional Contexts
by Indiana Castro, et al.
Vaccines 2023, 11(10), 1616; https://doi.org/10.3390/vaccines11101616 - 19 Oct 2023
Abstract
The COVID-19 pandemic posed challenges to communicating accurate information about vaccines because of the spread of misinformation. The European Medicines Agency (EMA) tried to reassure the public by communicating early on about the development and approval of COVID-19 vaccines. The EMA surveyed patients/consumers...
COVID-19 cases associated with testing policies in 34 highly democratic countries, 2020-2022
Leon S. Robertson
Abstract
COVID-19 testing policies varied in time from testing only the symptomatic, testing the symptomatic and persons at higher risk of severe disease, on-demand testing for people who wanted one, and two periods of government-imposed mass testing in Slovakia. Using Poisson regression, this study examines the associations of COVID-19 cases during the times that the noted policies were in effect in 34 countries rated highest on democracy scores. Statistically corrected for other risk factors, increases in negative tests were associated with subsequent surges in cases when on-demand testing was promoted, particularly when coupled with poor contact tracing. Mass testing in Slovakia was associated with reduced spread of the virus for short periods but was deemed unsustainable. The data support the hypothesis that on-demand testing resulted in the unanticipated consequence of increased travel and increased exposure of travelers to the virus.

Real-world data: A systematic literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process
Konstantinos Zisis, Elpida Pavi, Mary Geitona, Kostas Athanasakis
medRxiv 2023.10.18.23297151; doi: https://doi.org/10.1101/2023.10.18.23297151

We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.
**Wellcome Open Research**
https://wellcomeopenresearch.org/browse/articles
[Accessed 21 Oct 2023]
*Selected Research*
No new digest content identified.

* * * * *

**Think Tanks**

**Brookings** [to 21 Oct 2023]
http://www.brookings.edu/
*Research*
No new digest content identified.

**Center for Global Development** [to 21 Oct 2023]
https://www.cgdev.org/
*All Research [Selected]*
No new digest content identified.

**Chatham House** [to 21 Oct 2023]
https://www.chathamhouse.org/
*Selected Analysis, Comment, Events*
No new digest content identified.

**Council on Foreign Relations** [to 21 Oct 2023]
https://www.cfr.org/media/news-releases
*New Releases [Selected]*
No new digest content identified.

**CSIS** [to 21 Oct 2023]
https://www.csis.org/
*Reports [Selected]*
**Centering PEPFAR in U.S. Global Health Security Strategies**

The CSIS Working Group on Reinvigorating U.S. Leadership on HIV/AIDS offers recommendations for advancing progress on reaching the goal of eliminating HIV as a global public health threat by 2030 while maximizing the contributions to pandemic preparedness and response.
*Brief* by Katherine E. Bliss — October 19, 2023

**Kaiser Family Foundation** [to 21 Oct 2023]
https://www.kff.org/search/?post_type=press-release
*Newsroom*
No new digest content identified.
**McKinsey Global Institute**  [to 21 Oct 2023]
https://www.mckinsey.com/mgi/overview
*Latest Research*
*No new digest content identified.*

**ODI [Overseas Development Institute]**  [to 21 Oct 2023]
*Publications [Selected]*
*No new digest content identified.*

**Pew Research Center**  [to 21 Oct 2023]
https://www.pewresearch.org/
*Latest Publications [Selected]*
*No new digest content identified.*

**Rand**  [to 21 Oct 2023]
https://www.rand.org/pubs.html
*Published Research [Selected]*
*Report*
**The Operational Risks of AI in Large-Scale Biological Attacks: A Red-Team Approach**
In this report, the authors address the emerging issue of identifying and mitigating the risks posed by the misuse of artificial intelligence—specifically, large language models—in the context of biological attacks and present preliminary findings.
Oct 16, 2023
Christopher A. Mouton, Caleb Lucas, Ella Guest

**Urban Institute**  [to 21 Oct 2023]
https://www.urban.org/publications
*New Research Publications - Selected*
*Brief*
**Research Within versus Outside Existing Systems: Framing and Studying the Effects of Structural Racism**
October 19, 2023

**World Economic Forum**  [to 21 Oct 2023]
https://agenda.weforum.org/press/
*Media*
**Global Experts Call for Interdisciplinary Approaches to Improve Decision-Making**
18.10.2023
::: A diverse network of more than 450 global experts at the World Economic Forum’s Annual Meeting of the Global Future Councils 2023 highlighted the value of interdisciplinary and multistakeholder solutions to economic, technological, societal and environmental challenges in the face of geopolitical and economic uncertainty.
::: The cross-cutting programme in Dubai addressed harnessing artificial intelligence, accelerating the green transition, reviving productivity, addressing antimicrobial resistance and stabilizing trade.
30 councils developed proposals for collaboration that can create transformative change in the next three years in each of their topic areas.

Public Consultations/Call for Papers

Call for Contributions - OHCHR analytical study on key challenges in ensuring access to medicines, vaccines and other health products (HRC resolution 50/13)
Office of the High Commissioner for Human Rights / Call for input / Treaty bodies
Deadline: 30 November 2023

Purpose:
To inform the OHCHR analytical study on key challenges in ensuring access to medicines, vaccines and other health products (HRC resolution 50/13)

Background:
Vaccine equity and access to medicines is a fundamental component of the full realization of the right to health. Vaccines, medicines and other health products must not only be produced and made available - they must also be accessible to all persons. Yet, access to vaccines, medicines and other health products remains disturbingly uneven in many places.

Council resolution 50/13 requests the Office of the High Commissioner for Human Rights (OHCHR) to prepare an analytical study on key challenges in ensuring access to medicines, vaccines and other health products to be presented to the Human Rights Council at the fifty-sixth session in June 2024. In order to collect inputs for this forthcoming report, OHCHR has published a short questionnaire available in English, Français and Español.

* * * * *
* * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.

Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in
health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.